Eledon’s ALS Antibody AT-1501 Renamed Tegoprubart
The investigational antibody therapy for amyotrophic lateral sclerosis (ALS), AT-1501, will now be called tegoprubart, its maker, Eledon…
Articles by Patricia Inácio, PhD
Gut Microbiome Changes Evident Before ALS Onset, Study Finds
A mouse model of amyotrophic lateral sclerosis (ALS) carrying a mutation in the SOD1 gene showed alterations in the gut…
Eikonoklastes Acquires License to Potential ALS Gene Therapy
Eikonoklastes Therapeutics has added a candidate gene therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases to…
NurOwn Dosing Likely to Continue for ALS Patients in Its EAP
Amyotrophic lateral sclerosis (ALS) patients who completed the expanded access protocol (EAP) for NurOwn may soon be eligible for…
Trial Planned of Retinal Tracer in Detecting ALS via Eye Exam
Amydis announced plans to launch a first clinical trial next year into the ability of its small molecule tracer to…
Dosing Begins in Phase 2 Trial of 3K3A-APC to Protect Patients’ Neurons
A Phase 2 trial of ZZ Biotech’s investigational therapy 3K3A-APC in people with amyotrophic lateral sclerosis (ALS) has started dosing…
CNM-Au8 Slows Disease Progression in Limb, Bulbar Onset ALS
CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), showed consistent clinical benefits in patients…
NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show
Brainstorm Cell Therapeutics‘ investigational cell-based therapy, NurOwn, might be able to slow disease progression and be of “meaningful”…
Prilenia Raises $43M to Advance Plans for Pridopidine
Prilenia Therapeutics has raised $43 million to support potential regulatory submissions and marketing of its lead candidate, pridopidine,…
Phase 3 Trial of FNP122, Oral Form of Edaravone, Starts Enrolling in Europe
A first patient has been enrolled in a Phase 3 clinical trial investigating FNP122, an oral formulation of edaravone being developed…